Experts at the Aids 2026 Conference in Rio de Janeiro have highlighted a significant disparity between emerging HIV prevention technologies and the funding constraints limiting their distribution worldwide. One year prior, the World Health Organization recommended governments prioritize access to lenacapavir, an injectable HIV prevention medication requiring only two annual doses. The medication is 99% effective in preventing sexually transmitted HIV for consistent users and addresses a critical gap for populations facing barriers to traditional treatments.
Lenacapavir offers particular advantages for economically disadvantaged communities, those experiencing stigma, and people in remote areas where accessing daily pills or bimonthly injections proves difficult. Mathematical modeling suggested widespread availability could prevent 41% of new HIV infections in South Africa, Zimbabwe and western Kenya. However, the timing of this recommendation coincided with significant changes in US foreign aid allocation, with USAID previously accounting for 73% of donor-funded HIV prevention resources globally. As of July 2026, reports indicate a dramatic decline in HIV prevention investment across multiple regions.
International Aids Society president Beatriz Grinsztejn emphasized that funding reductions are undermining both medication availability and the capacity of organizations to reach target populations. Peer outreach workers—essential for engaging vulnerable groups including people who inject drugs—have been among the first positions cut by affected organizations. When organizations reduce locations or services due to funding constraints, at-risk communities lose local points of contact and trust, ultimately preventing innovative treatments from reaching those most in need.
Additionally, geographic disparities in medication access persist. Pharmaceutical companies classify certain Latin American nations as upper-middle-income countries, restricting them from affordable generic programs despite significant contributions to clinical trial development. Experts expressed concern that these combined obstacles may prevent achievement of the UNAIDS goal to eliminate AIDS as a public health threat by 2030.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI